Fengyu Chu

Fengyu Chu

Auto-generated profile, based on publicly available information

Fengyu Chu

Shanxi Provincial Key Laboratory for Medical Molecular Cell Biology, Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education and Institute of Biomedical Sciences, Shanxi University, Taiyuan, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2025 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
CYCaiting Yang
Caiting Yang
FCFengyu Chu
Fengyu Chu
XCXiaoli Chen
Xiaoli Chen
FMFanqi Meng
Fanqi Meng
YLYinhao Li
Yinhao Li
WYWei Yuan
Wei Yuan
Glutamine: fructose-6-phosphate amidotransferase (GFAT), a conserved enzyme across prokaryotic and eukaryotic species, is the first and rate-limiting step in the hexosamine biosynthetic pathway (HBP), diverting 2–5% of fructose-6-phosphate derived from glucose toward the synthesis of uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), a key substrate for the glycosylation of proteins and lipids. While substantial progress has been made in elucidating the basic biochemical properties and regulatory mechanisms of GFAT, its functional impact on pathological processes remains incompletely understood. Emerging evidence implicates GFAT in a spectrum of human diseases, including cancer, diabetes, cardiovascular disorders, and neurodegenerative conditions such as Alzheimer’s disease. This review aims to provide a comprehensive synthesis of current insights into GFAT’s role in disease etiology, with the goal of informing future research and therapeutic strategies targeting this essential metabolic regulator.